The AI in Genomics Market will grow at a CAGR of 42.8% during the Forecast period to reach $6.22 billion by 2029. Artificial intelligence (AI) has tremendous potential in genomics. AI or machine learning (ML) helps to improve understanding of the hidden patterns in complex and large genomics data sets from clinical and research projects. AI in genomics helps identify genetic disorders and the primary kind of cancer, predict the specific diseases progress in a patient, identify disease-causing genomic variants, and improve the function of gene editing tools.
The growth of this market is mainly attributed to the increasing use of AI in healthcare, particularly genomics, growing investments in genomic research and AI, and rising focus on reducing the turnaround time in drug discovery and diagnostics. Moreover, the rising adoption of machine learning (ML) in personalized/precision medicine and the emergence of local and regional start-ups in AI and genomics offer significant opportunities for market growth.
Here are the top 10 companies operating in the Artificial Intelligence in Genomics Market
Founded in 1975 and headquartered in Washington, U.S., Microsoft Corporation is a technology company that develops and supports software, services, solutions, and devices. The company offers cloud-based solutions, solution support, consulting services, cross-device productivity applications, operating systems, server applications, business solutions, desktop and server management tools, software development tools, and video games, PCs, tablets, gaming and applications entertainment consoles, and other intelligent devices and related accessories.
Microsoft operates through three segments, namely, Productivity and Business Process, Intelligent Cloud, and More Personal Computing. The company operates in the AI in genomics market through its Intelligent Cloud segment, which offers public, private and hybrid server products and cloud services. This segment is further categorized into server products and cloud services and enterprise services.
The company has a direct presence through its R&D sites and data centers in China, India, Ireland, the Netherlands, Singapore, South Korea, Australia, Canada, China, France, Germany, India, Israel, Japan, the Netherlands, and the U.K. It indirectly licenses products and services through licensing solution partners (LSP), value-added resellers (VAR), distributors, and retailers and distributes retail products through authorized replicators, independent non-exclusive distributors, resellers, and retail outlets.
NVIDIA Corporation (U.S.)
Founded in 1993 and headquartered in California, U.S., NVIDIA Corporation is a technology company engaged in designing graphics processing units, application programming interfaces, and related multimedia software. The company operates in two business segments, namely, Graphics and Compute & Networking. The Compute & Networking segment includes data center platforms, systems for AI, automotive AI Cockpits, NVIDIA AI Enterprise, and other software.
NVIDIA operates in the AI in genomics market through an application framework, NVIDIA Clara, designed for AI-powered genomics, imaging, and the development and deployment of smart sensors. Its products are sold across gaming, automotive, data center, and professional visualization markets. The company has a direct presence in nearly 32 countries, including the U.S., India, China, Japan, Poland, Russia, Hungary, Switzerland, Sweden, Denmark, and the U.K., through its 50 offices.
Deep Genomics Incorporated (Canada)
Founded in 2015 and headquartered in Toronto, Canada, Deep Genomics Incorporated is a biotechnology research company that works in artificial intelligence (AI) and its applications in genetic mutations and the discovery of personalized therapies. The company provides AI in genomics software, AI workbench series, which enables the discovery of CNS diseases like Frontotemporal Dementia, Niemann-Pick Disease Type C, Pediatric Epilepsy, Parkinson’s Disease, and metabolic diseases such as Wilson Disease and Refractory Gout.
Deep Genomics has a direct presence in North America in Toronto and Boston. In 2019, its intelligence-based drug discovery platform was identified as a novel treatment target and corresponding drug candidate for Wilson’s disease.
In January 2020, the company closed its SERIES B round with USD 40 million in new investment to develop new treatments for rare genetic diseases and to expand its AI discovery platform to support the discovery and development of novel therapies for common disorders. Deep Genomics has a robust R&D pipeline to enable the discovery of new treatments for diseases such as metabolic and central nervous systems using its AI Workbench platform.
Fabric Genomics, Inc. (U.S.)
Founded in 2009 and headquartered in California, U.S., Fabric Genomics, Inc. is a biotechnology research company that offers AI-based platforms for NGS analysis, interpretation and clinical reporting for rare diseases, hereditary risk, cancer testing, and genomics platforms. The company offers solutions for application areas such as hereditary screening risk, rare disease diagnosis, rapid NICU testing, pediatric panels, and country genome projects. It also offers technology and services in panel interpretation, WGS/WES interpretation, clinical services, and fabric enterprise platforms.
Fabric Genomics has a direct presence through satellite offices and sales in the U.K. and the U.S.. Some of its investors are F. Hoffmann-La Roche Ltd (Switzerland), University of Pittsburgh Medical Center (UPMC) (U.S.), Ping A Ventures (China), LDV Partners (U.S.), and Foresite Capital (U.S.).
Founded in 2013 and headquartered in California (U.S.), Data4Cure is a biotechnology research company that provides a biomedical intelligence platform combining system biology, machine learning, semantic AI engine, and advanced machine learning. Based on its biomedical intelligence cloud platform, the company offers solutions in genomics data management and research, clinical trial analysis, target discovery, network and pathway analysis, drug repositioning, disease subtype analysis, single cell and cell deconvolution analysis, and predictive modeling.
Data4Cure operates in AI in genomics by offering solutions based on the biomedical intelligence cloud platform. The biomedical intelligence cloud platform is designed to enable the learning and analysis of heterogeneous biomedical data. Furthermore, this platform has analyzed over 10 million biomedical samples using tools such as DataHub, Biomedical App Engine, and The CURIE Knowledge Graph.
Predictive Oncology Inc. (U.S.)
Founded in 2002 and headquartered in Minnesota, U.S., Predictive Oncology Inc. focuses on applying AI to develop personalized cancer therapies. The company has four reportable segments, namely, Helomics, zPREDICTA, Soluble, and Skyline. It operates in the AI in genomics market through the Helomics segment by providing AI-driven clinical testing and contract research services platform. This segment provides a next-generation platform for pharmaceutical and diagnostic companies to accelerate the development of new precision therapies. This platform has generated a genomic knowledge base from testing nearly 150,000 clinical cases covering 137 tumor types.
Predictive Oncology has offices in Minnesota, U.S., and its subsidiary Helomics (U.S.) deals with AI in genomics in Pennsylvania (U.S.). The company serves clinical research laboratories, academic research laboratories, and pharmaceutical companies globally. Furthermore, in February 2021, the company initiated an in-house drug repurposing project focused on ovarian cancer, using PeDAL, its proprietary AI-driven, patient-centric discovery platform.
Founded in 2015 and headquartered in Illinois, U.S., Tempus is a data-driven technology company focused on accelerating the discovery of novel targets, predicting the effectiveness of treatments, and diagnosing multiple diseases. The company has developed a novel artificial intelligence platform, Tempus ONE, to generate, collect, structure, and analyze genomic data to aid precision medicine. This AI-driven platform provides solutions for genomic profiling, clinical trial matching, data collaborations, companion diagnostics, and multiomics.
Tempus has partnered with over 120 biopharmaceutical companies and is connected with more than 50% of the academic medical centers in the U.S.
SOPHiA GENETICS SA (Switzerland)
Incorporated in 2011 and headquartered in Saint-Sulpice, Switzerland, SOPHiA GENETICS is a healthcare technology company that offers a cloud-based Software-as-a-Service platform. Its proprietary platform combines genotypic and phenotypic information in oncology, rare and inherited diseases, cardiology, neurological disorders, and metabolism for discoveries, treatment decisions, and drug development applications. The company operates in the AI in genomics market by providing a proprietary platform for genomics, SOPHiA, which offers genomics applications across oncology, rare diseases, infectious diseases, cardiology, neurology, metabolism, and other disease areas. This platform helps analyze more than 910,000 genomic profiles and has been utilized in clinical trials and research projects discussed in more than 330 peer-reviewed publications.
SOPHiA GENETICS has a direct presence through headquarters and laboratory facilities in Switzerland, France, the U.S., the U.K., and Brazil. As of December 2021, the company served 790 hospitals, laboratories, and biopharma customers in over 70 countries globally through the SOPHiA platform and related solutions, products and services. Some of its subsidiaries operating in the AI in genomics market are SOPHiA GENETICS S.A.S (France), SOPHiA GENETICS LTD (U.K.), SOPHiA GENETICS, Inc. (U.S.), and SOPHiA GENETICS PTY LTD (Australia).
Foun headquartered in California, U.S., Illumina, Inc. develops, manufactures, and markets life sciences tools and integrated systems for functional and variational analysis of genes. The company provides array and sequence-based solutions such as integrated sequencing and microarray systems, consumables, and genetic and genomic analysis tools and operates in two reportable business segments, namely, Core Illumina and GRAIL. Illumina operates in the AI in genomics market through the Core Illumina business segment. Additionally, it offers its services to government laboratories, academic institutions, hospitals, genomic research centers, biotechnology companies, consumer genomics companies, pharmaceuticals, and commercial molecular diagnostic laboratories
Illumina operates in around 28 countries globally and has commercial offices in the U.S., Australia, Germany, China, France, Japan, Brazil, the Netherlands, the U.K., Singapore, and South Korea, with manufacturing and R&D operations in the U.S., Singapore, and the U.K.. Some of its major subsidiaries are Illumina Cambridge Ltd (U.K.), Illumina Belgium BVBA (Belgium), Illumina Australia Pty. Ltd (Australia), and Illumina Canada ULC (Canada
BenevolentAI Limited. (U.K.)
Founded in 2013 and headquartered in London, U.K., BenevolentAI Limited is a clinical-stage AI-enabled drug discovery company that uses machine learning and advanced AI to find more potential medications. Its powerful computational R&D Benevolent Platform helps AI-enabled drug development & discovery. The company generates revenue from its proprietary platform’s licensing and collaboration partnerships. Furthermore, BenevolentAI has produced a substantial clinical and pre-clinical pipeline of over 20 drug programs, including one clinical-stage program in atopic dermatitis and many other early discovery programs.
The company serves drug discovery companies in the U.K. market and has a research facility in Cambridge (U.K.) and an office in New York (U.S.)
